Analyzing the Biochemical, Clinical, and Hormonal Characteristics of Patients with Polycystic Ovary Syndrome

Year 2021, Volume: 38 Issue: 4, 478 - 484, 09.10.2021

Tuğba Gürbüz , Şebnem Alanya Tosun

Abstract

Aim: To analyze the biochemical, clinical, and hormonal characteristics of patients with four phenotypes of Polycystic ovary syndrome (PCOS).
Method: A total of 225 patients admitted to xxx Gynecology and Obstetric outpatient clinic and xxx University Faculty of Medicine Gynecology and Obstetric clinic between January 2019 and January 2020 diagnosed as PCOS and healthy controls were included in the study. The revised Rotterdam criteria were applied to diagnose PCOS. The patients with PCOS were divided into Type I classic, Type II classic, Ovulatory and Normoandrogenic PCOS. Biochemical, clinical, and hormonal values were compared.
Results: The mean age of the participants is 28 (±5.7) and the mean body mass index (BMI) is 26.15(±5.36). The mean Ferriman Gallwey Score (FGS) is 7.4(±5.4), which is normal. There is a statistically significant difference between the four PCOS groups and control group in terms of age (p-value=0.000), BMI (p-value=0.000), Luteinizing hormone / Follicle stimulating hormone (LH/FSH) (p-value=0.000), and fasting blood sugar (p-value=0.01). There is a statistically significant difference among the four phenotypes in terms of BMI (p-value =0.002), LH/FSH (p-value =0.000), LH (p-value =0.000), free T4 (p-value =0.01), fasting insulin (p-value =0.001), total testosterone (p-value =0.000), FGS (p-value =0.000), etc.
Conclusion: Age, BMI, LH/FSH, FSH, LH, fasting blood sugar, and hirsutism are good predictors of PCOS.

Keywords

Polycystic Ovary Syndrome, Phenotype, Anovulation, Hyperandrogenism, Hirsutism

Project Number

Yok

References

• 1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol and Metab 2004; 89: 2745-9.
• 2. Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop GroupRevised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25.
• 3. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rationale approach. In: Dunaif A, Givens JR, Haseltine F, Merriam GR, eds. Polycystic ovary syndrome. Boston: Blackwell Scientific 1992;377–84.
• 4. Nahar K, Mahfuza G, Begum SA, Khatun K, Islam MR. Clinical, Biochemical and Hormonal Profile of Polycystic Ovary Syndrome. Journal of National Institute of Neurosciences Bangladesh. 2017;3(2):94-8.
• 5. Xu X, Shi Y, Cui Y, Ma J, Che L, Chen ZJ. Endocrine and metabolic characteristics of polycystic ovary syndrome in Chinese women with different phenotypes. Clin Endocrinol (Oxford) 2012;76:425–30.
• 6. Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG 2006;113:1148-59.
• 7. Shroff R, Syrop CH, Davis W, Van Voorhis BJ, Dokras A. Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril 2007; 88(5):1389-95.
• 8. Yilmaz M, Isaoglu U, Delibas IB, Kadanali S. Anthropometric, clinical and laboratory comparison of four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. J Obstet Gynecol Research 2011; 37:1020–26.
• 9. Dewailly D, Catteau-Jonard S, Reyss AC, Leroy M, Pigny P Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. J Clin Endocrinol Metabol 2006;91:3922–7.
• 10. Pehlivanov B. and Orbetzova M .Characteristics of different phenotypes of polycystic ovary syndrome in a Bulgarian population. Gynecol Endocrinol 2007; 23, 604–9.
• 11. Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 2005;90:2545–9.
• 12. Jamil AS, Alalaf SK, Al-Tawil NG, Al-Shawaf T. Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria. Archives of gynecology and obstetrics. 2016;293(2):447-56.
• 13. Sahmay S, Atakul N, Oncul M, Tuten A, Aydogan B, Seyisoglu H.Serum anti-mullerian hormone levels in the main phenotypes of polycystic ovary syndrome Eur J Obstet Gynecol Reprod Biol 2013; 170: 157-61.
• 14. Guastella E, Longo RA, Carmina E. Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertil Steril 2010;94:2197– 201.
• 15. Thathapudi S, Kodati V, Erukkambattu J, Katragadda A, Addepally U, Hasan Q. Anthropometric and Biochemical Characteristics of Polycystic Ovarian Syndrome in South Indian Women Using AES-2006 Criteria. Int J Endocrinol Metab 2014;12.
• 16. Farhan YM, Taher MA & Alhadithy EM. Comparative study on cardiovascular risk factors in newly diagnosed patients with polycystic ovary syndrome (PCOS) and PCOS patients who are on drug metformin. Internat J Sci Nat 2012; 3 (1): 24-9.
• 17. Kucur SK, Yüksel B, Seven A, Polat M, Keskin N, Aksoy AN. Farklı Dört Polikistik Over Sendromu Fenotipinin Klinik Ve Laboratuvar Değerlerinin Karşılaştırılması. Mustafa Kemal Üniversitesi Tıp Dergisi. 2016; 30;7(26).
• 18. Chae SJ, Kim JJ, Choi YM, Hwang KR, Jee BC, Ku SY, Suh CS, et al. Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women. Hum Rep-rod 2008;23:1924–31.
• 19. Daan NM, Louwers YV, Koster MP, Eijkemans MJ, de Rijke YB, Lentjes EW, et al. Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk? Fertil Steril. 2014;102:1444-51.